A Digital Cardiology-Embedded Obesity Platform Produces Sustained Clinical and Financial Outcomes, Redefining Cardiovascular Prevention
- 1 University of California, San Francisco , San Francisco, CA, USA
- 2 University of Damascus , Damascus, Syria
- 3 University of Santo Tomas , Manila, Philippines
- 4 Enara Health , San Mateo, CA, USA
Background
Obesity is a major contributor to cardiovascular diseases, including hypertension, dyslipidemia, atrial fibrillation, and heart failure. Despite this, cardiology practices often lack structured tools to address obesity as a modifiable risk factor. We evaluated the clinical and financial impact of a digitally delivered, multidisciplinary obesity care platform embedded within cardiology clinics.
Methods
This retrospective cohort study analyzed outcomes from 2,400 adults with obesity enrolled in a digital-first, cardiology-integrated obesity management program. The intervention included physician-directed care, nutritional and exercise therapy, behavioral health support, and optional anti-obesity pharmacotherapy. Program delivery was supported by connected home scales, telehealth visits, and a data-driven care coordination platform. Primary outcomes included percent weight loss sustained at ≥18 months, cardiometabolic markers (HbA1c, systolic blood pressure, LDL cholesterol), and reimbursement metrics. A subanalysis was conducted on 792 patients across one cardiology practice to assess financial performance.
Results
At ≥18 months, the cohort achieved a mean weight loss of 41 lbs (15.3%). Over 70% of long-term enrollees maintained ≥10% weight loss, and more than 40% achieved ≥15% loss. When stratified by pharmacotherapy, participants receiving GLP-1RA (61.4% of the cohort), non–GLP-1 AOMs (12.4%), or no pharmacotherapy (11.0%) demonstrated clinically meaningful weight loss at both thresholds. Cardiometabolic parameters improved significantly: HbA1c (-1.1%), systolic blood pressure (-8 mmHg), and LDL cholesterol (-14 mg/dL). In the financial subanalysis, 83% of claims were reimbursed, with an average collection of $311 per patient per month, translating into a new service line for the practice with $3 million in annualized revenue.
Discussion
The greatest barrier to cardiovascular risk reduction in obese patients is not the lack of effective treatments, but the lack of a structured system to deliver them. This study shows that embedding obesity care within cardiology practices enables patients to achieve sustained weight loss, including ≥15% loss for over 40% of participants, and meaningful improvements in blood pressure, cholesterol, and HbA1c. Notably, even patients not on pharmacotherapy achieved clinically significant results, highlighting the power of a coordinated, digital-first, multidisciplinary approach. Beyond patient outcomes, the program generates substantial revenue, demonstrating that obesity management can be both an essential and financially sustainable pillar of modern cardiovascular care.
Conclusion
Embedding a digital, multidisciplinary obesity platform within cardiology practices produced sustained weight loss and meaningful cardiometabolic improvements while generating a financially sustainable new service line. The model offers cardiology practices a scalable approach to deliver effective obesity care alongside core cardiovascular prevention.
Related research
Care Factors Associated With Sustained 15% Weight Loss at Three Years in Patients Not Taking AOMs
1 in 5 Enara patients lost over 15% of their weight at 3 years - with no medications. Consistent, digital-first engagement set the high achievers apart.
April 1, 2026
Beyond Weight Loss Percent: Key Factors Associated With SMM Preservation in an Obesity Care Program
Not all weight loss is good weight loss. High achievers preserved skeletal muscle mass while losing fat - and the difference came from dietary and pharmacological intensity, not exercise volume.
April 1, 2026
Impact of Medicaid vs Commercial Insurance Status on Weight Loss Outcomes With and Without AOMs
Even when motivation is the same, access isn't. This study shows that Medicaid patients can achieve outcomes comparable to commercially insured peers when given access to anti-obesity medications.
April 1, 2026